Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, c… Read more
Duality Biotherapeutics, Inc. (4ZB) - Net Assets
Latest net assets as of June 2025: €2.91 Billion EUR
Based on the latest financial reports, Duality Biotherapeutics, Inc. (4ZB) has net assets worth €2.91 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.18 Billion) and total liabilities (€1.26 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.91 Billion |
| % of Total Assets | 69.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Duality Biotherapeutics, Inc. - Net Assets Trend (2022–2024)
This chart illustrates how Duality Biotherapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Duality Biotherapeutics, Inc. (2022–2024)
The table below shows the annual net assets of Duality Biotherapeutics, Inc. from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-2.02 Billion | -79.90% |
| 2023-12-31 | €-1.12 Billion | -46.13% |
| 2022-12-31 | €-769.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Duality Biotherapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 149221000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €223.35 Million | % |
| Total Equity | €-2.02 Billion | 100.00% |
Duality Biotherapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Duality Biotherapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grupo Cementos de Chihuahua S.A.B. de C.V
PINK:GCWOF
|
$1.45 Billion |
|
Weibo Corp
NASDAQ:WB
|
$1.45 Billion |
|
Steelcase Inc
NYSE:SCS
|
$1.45 Billion |
|
APERAM S.A. NY SHS/1 O.N.
F:7AAN
|
$1.45 Billion |
|
Exide Industries Limited
NSE:EXIDEIND
|
$1.45 Billion |
|
East Group Co Ltd
SHE:300376
|
$1.45 Billion |
|
Sharplink Gaming Ltd
NASDAQ:SBET
|
$1.45 Billion |
|
Hwa Create Corp Ltd
SHE:300045
|
$1.45 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Duality Biotherapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,123,913,000 to -2,021,899,000, a change of -897,986,000.
- Net loss of 1,050,434,000 reduced equity.
- Other factors increased equity by 152,448,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.05 Billion | -51.95% |
| Other Changes | €152.45 Million | +7.54% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Duality Biotherapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €-9.25 | €32.20 | x |
| 2023-12-31 | €-13.51 | €32.20 | x |
| 2024-12-31 | €-24.31 | €32.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Duality Biotherapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -54.11%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | -24193.13% | 0.00x | 0.00x | €-310.18 Million |
| 2023 | 0.00% | -20.01% | 1.19x | 0.00x | €-245.12 Million |
| 2024 | 0.00% | -54.11% | 0.93x | 0.00x | €-848.24 Million |
Industry Comparison
This section compares Duality Biotherapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Duality Biotherapeutics, Inc. (4ZB) | €2.91 Billion | 0.00% | 0.43x | $1.45 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |